Lonza Group Ltd
LO3A
Company Profile
Business description
Lonza Group is a contract development and manufacturing organization. It operates under four segments: small molecules, biologics, cell and gene, and capsules and health ingredients. Lonza derives its revenue primarily from long-term supply agreements with pharmaceutical customers. The company provides development and manufacturing services throughout the entire lifecycle of a product, from drug research to commercial supply. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic institutions, and government research organizations.
Contact
Muenchensteinerstrasse 38
Basel4002
CHET: +41 613168111
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2026
Employees
16,866
Stocks News & Analysis
stocks
Alphabet raises $80 billion for AI efforts
$10 billion private placement to Berkshire Hathaway as part of equity raise.
stocks
SpaceX: What investors need to know about its enormous upcoming IPO
Morningstar launches research coverage of SpaceX.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,998.90 | 21.40 | -0.24% |
| CAC 40 | 8,209.09 | 62.50 | 0.77% |
| DAX 40 | 25,124.17 | 121.13 | 0.48% |
| Dow JONES (US) | 51,307.79 | 228.91 | 0.45% |
| FTSE 100 | 10,373.51 | 34.56 | 0.33% |
| HKSE | 26,038.32 | 640.14 | 2.52% |
| NASDAQ | 27,093.90 | 7.09 | 0.03% |
| Nikkei 225 | 67,705.01 | 970.77 | 1.45% |
| NZX 50 Index | 13,137.64 | 33.07 | -0.25% |
| S&P 500 | 7,609.78 | 9.82 | 0.13% |
| S&P/ASX 200 | 8,761.80 | 18.00 | -0.21% |
| SSE Composite Index | 4,075.10 | 17.36 | 0.43% |